Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ /6821.HK), recently announced that its Fengxian commercial manufacturing site in Shanghai...
-
Lifecore Biomedical and Indomo sign new agreement to support innovative drug/device combination acne treatment.
-
OXB announces date for Capital Markets Day and participation in upcoming investor conferences Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy...
-
Revenues at the upper end of guidance and pivot to EBITDA profitability - expectations for 2026 unchanged and guidance reiterated Revenues expected to increase c.30% as OXB continues to execute its...
-
~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to...
-
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”),...
-
Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts...
-
Halo Pharma to become a stand-alone Drug Product CDMO.
-
Acquisition adds further specialist biostatistics, data management, and medical writing expertise to Evestia Clinical’s full-service offering and strengthens its presence in Germany and across Europe ...
-
Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031"...